Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Natasha Richesin

Physician Assistant Athens, TN Physician Assistant

NPI 1528731502 CMS profile 11142470

1031 W Madison Ave Ste 1, Athens, TN 37303

Open in the dashboard

General payments

$3,459

207 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Natasha Richesin of Athens, TN is reported in the CMS Open Payments database as having received $3,459 across 207 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 87th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $784 38
2024 General $926 54
2023 General $881 53
2022 General $783 56
2021 General $85 6

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Natasha Richesin
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Natasha Richesin were reported at $784. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Natasha Richesin Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $85 $132 $37–$438 $132
2022 $783 $155 $48–$522 $149
2023 $881 $167 $52–$557 $160
2024 $926 $178 $55–$600 $164
2025 $784 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Novo Nordisk Inc $860 61 payments
  2. Pfizer Inc. $343 17 payments
  3. Lilly USA, LLC $341 23 payments
  4. AbbVie, Inc. $315 18 payments
  5. Novartis Pharmaceuticals Corporation $286 14 payments
  6. GlaxoSmithKline, LLC. $192 10 payments
  7. Bayer HealthCare Pharmaceuticals Inc. $164 9 payments
  8. Salix Pharmaceuticals, a division of Bausch Health US, LLC $163 8 payments
  9. Amgen Inc. $133 10 payments
  10. Xeris Pharmaceuticals, Inc. $122 6 payments
  11. Other $540 31 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $3,459 207 payments
Products named General payments · program years 2021–2025
  1. Ozempic $496 29 payments
  2. RYBELSUS $496 29 payments
  3. COMIRNATY $265 13 payments
  4. PREVNAR 20 $262 13 payments
  5. Wegovy $253 21 payments
  6. MOUNJARO $232 14 payments
  7. LEQVIO $232 10 payments
  8. ABRYSVO $204 10 payments
  9. ZEPBOUND $178 12 payments
  10. SHINGRIX $175 9 payments
  11. Other $2,570 152 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 41 drugs

Part D claims

918

Median for Physician Assistant: 241

Drug cost

$41,868

Median for Physician Assistant: $4,110

Branded share of claims

18.2%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 24 $18,512
Ozempic Semaglutide Brand 11 $16,268
Albuterol Sulfate Hfa Albuterol Sulfate Brand 32 $784
Atorvastatin Calcium Generic 43 $494
Levothyroxine Sodium Generic 65 $466
Fluticasone Propionate Generic 32 $315
Valsartan-Hydrochlorothiazide Valsartan/Hydrochlorothiazide Brand 11 $304
Omeprazole Generic 31 $298
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 37 $284
Prednisone Generic 49 $278

The 10 drugs with the highest cost, of 41 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 89 billing codes

Paid by Medicare

$58,027

Of which drugs: $54

Medicare patients

396

Average age 76

Services billed

2,037

234 women, 162 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 46%
Diabetes 37%
Ischemic heart disease 28%
Chronic kidney disease 27%
Atrial fibrillation 22%
Cancer 16%
Depression 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 16 128 $10

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 25 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ZEPBOUND
  • Lilly USA, LLC $80
$80 — —
MOUNJARO
  • Lilly USA, LLC $79
$79 — —
LEQVIO
  • Novartis Pharmaceuticals Corporation $75
$75 — —
RYBELSUS
  • Novo Nordisk Inc $72
$72 — —
Ozempic
  • Novo Nordisk Inc $72
$72 11 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 25 in the dashboard with a free account

Records

207 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record